Mideast medicines up 18% yearly
United Arab Emirates: Tuesday, March 25 - 2008 at 09:13
According to IIR Middle East, the Middle East pharmaceutical market grows between 15 and 18% annually, cited Gulf News, due to increasing public and private investment in the sector. IIR is organizing the International Pharmaceutical and Biotechnology Exhibition in the region to cover key areas in drug discovery, clinical trials and manufacturing through to biologics, devices, global licensing and regulatory aspects.
- ADD ARTICLE TO
-
Facebook
del.icio.us
Digg">
Also consider reading:
- » Maternity hospital for Sharjah
- » Fewer UAE nationals seek care abroad
- » e-TQM offers health masters course
- » Healthy bones campaign launched
- » Oman to build $1bn healthcare city
- » Saudi okays center for blood disease
- » UAE scientists honoured
- » Bird flu sweeps Egypt
- » Dubai hospital names CEO
- » Pfizer makes Dubai its regional HQ
Medilyn Manibo, Assistant News EditorTuesday, March 25 - 2008 at 09:13 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Index : Healthcare
Browse related articles
Browse related articlesToday's most read articles:
Most read articles the past week:
Disclaimer:
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
Web Feeds